10.1055/a-2406-7492
We read with great interest the study by Maselli et al. [1] about the potential role of PuraStat in endoscopic management and prevention of
gastrointestinal bleeding. This real-world investigation, based on an Italian registry
of 401 patients treated with this novel hemostatic agent, provides valuable insights.
The relatively large cohort and the prospective design convincingly demonstrate the
efficacy and safety of PuraStat for managing iatrogenic bleeding and preventing delayed
post-procedure hemorrhage.
We fully agree with the authors about the utility of PuraStat for both active “oozing”
bleeding and prevention of delayed rebleeding, particularly following challenging
polypectomies. In our clinical practice, we often prefer powder-based hemostatic agents
for diffuse bleeding; however, their utility is frequently hindered by risk of clogging
and impaired endoscopic visibility.
Beyond these observations, we would like to highlight a critical aspect of the study
by Maselli et al. [1] about application of PuraStat in cases of non-iatrogenic active gastrointestinal
hemorrhage. Existing data on this indication in gastrointestinal endoscopy are scarce,
with limited reports such as its use alongside ligation for active diverticular bleeding
in the colon [2]. A key innovation of the study by Maselli et al. [1] lies in the use of PuraStat for active “oozing” bleeding as well as for severe acute
hemorrhage as a secondary treatment. However, detailed descriptions of the five cases
of “arterial spurt” bleeding included in the analysis were not provided in the manuscript,
and lack of this information limits reader ability to clearly understand what characteristics
of the active gastrointestinal bleeding lesions could really benefit from PuraStat
treatment. Because the authors declare that in these cases PuraStat was used in conjunction
with other hemostatic techniques (mechanical, injective, or thermal), it can be inferred
that the approach was aimed at preventing delayed rebleeding, resulting in a technical
success (no rebleeding reported in Table 4).
In conclusion, we concur with the authors about the promising and expanding role of
PuraStat in management of gastrointestinal bleeding. Nonetheless, only prospective
comparative studies can definitely establish its indications, efficacy in bleeding
control and prevention, and impact on major clinical outcomes such as hospitalization
length, morbidity, and mortality rates.
Bibliographical Record
Elettra Merola, Giovanni Mario Pes, Maria Pina Dore. PuraStat for gastrointestinal
bleeding management: Effective approach for endoscopic prevention and rescue therapy.
Endosc Int Open 2024; 12: a25506600.
DOI: 10.1055/a-2550-6600
